JP6464395B2 - マクロファージを刺激する１受容体ｍｓｔｒ１のキノリン阻害剤 - Google Patents

マクロファージを刺激する１受容体ｍｓｔｒ１のキノリン阻害剤 Download PDF

Info

Publication number
JP6464395B2
JP6464395B2 JP2016517180A JP2016517180A JP6464395B2 JP 6464395 B2 JP6464395 B2 JP 6464395B2 JP 2016517180 A JP2016517180 A JP 2016517180A JP 2016517180 A JP2016517180 A JP 2016517180A JP 6464395 B2 JP6464395 B2 JP 6464395B2
Authority
JP
Japan
Prior art keywords
ethyl
pyrazole
pyrimidin
carboxamide
oxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016517180A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016520627A (ja
Inventor
シャット，オリバー
エスダール，クリスティーナ
シュルツ−ファデムレヒト，カルステン
アイコッフ，ヤン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lead Discovery Center GmbH
Original Assignee
Lead Discovery Center GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lead Discovery Center GmbH filed Critical Lead Discovery Center GmbH
Publication of JP2016520627A publication Critical patent/JP2016520627A/ja
Application granted granted Critical
Publication of JP6464395B2 publication Critical patent/JP6464395B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016517180A 2013-06-06 2014-05-07 マクロファージを刺激する１受容体ｍｓｔｒ１のキノリン阻害剤 Expired - Fee Related JP6464395B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13002926.7 2013-06-06
EP13002926 2013-06-06
PCT/EP2014/001231 WO2014194975A1 (en) 2013-06-06 2014-05-07 A quinoline inhibitor of the macrophage stimulating 1 receptor mst1 r

Publications (2)

Publication Number Publication Date
JP2016520627A JP2016520627A (ja) 2016-07-14
JP6464395B2 true JP6464395B2 (ja) 2019-02-06

Family

ID=48576706

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016517180A Expired - Fee Related JP6464395B2 (ja) 2013-06-06 2014-05-07 マクロファージを刺激する１受容体ｍｓｔｒ１のキノリン阻害剤

Country Status (11)

Country Link
US (1) US9481668B2 (enExample)
EP (1) EP3003315B1 (enExample)
JP (1) JP6464395B2 (enExample)
CN (1) CN105307656B (enExample)
AU (1) AU2014277262B2 (enExample)
CA (1) CA2914500C (enExample)
DK (1) DK3003315T3 (enExample)
ES (1) ES2663393T3 (enExample)
IL (1) IL242915B (enExample)
NO (1) NO3003315T3 (enExample)
WO (1) WO2014194975A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021030358A1 (en) 2019-08-12 2021-02-18 Regeneron Pharmaceuticals, Inc. Macrophage stimulating 1 receptor (mst1r) variants and uses thereof
TWI812301B (zh) * 2021-06-24 2023-08-11 南韓商Ｌｇ化學股份有限公司 作為ｒｏｎ抑制劑之新穎尿素衍生物化合物
TW202315628A (zh) * 2021-06-24 2023-04-16 南韓商Ｌｇ化學股份有限公司 作為ｒｏｎ抑制劑之新穎吡啶衍生物化合物
JP2025500917A (ja) 2021-12-16 2025-01-15 キネート バイオファーマ インク． Ｍｅｔキナーゼの阻害剤
WO2025101652A1 (en) * 2023-11-07 2025-05-15 The Scripps Research Institute Selective mammalian sterile 20-like kinase 1 (mst1) modulator compounds as therapeutics for diabetes and liver regeneration
KR102921178B1 (ko) * 2023-11-16 2026-02-02 (주)신테카바이오 헤테로아릴 유도체 화합물 및 이의 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
US20110053931A1 (en) 2006-06-08 2011-03-03 John Gaudino Quinoline compounds and methods of use
EP2423208A1 (en) * 2010-08-28 2012-02-29 Lead Discovery Center GmbH Pharmaceutically active compounds as Axl inhibitors

Also Published As

Publication number Publication date
AU2014277262A1 (en) 2016-01-21
CN105307656B (zh) 2019-02-19
CA2914500A1 (en) 2014-12-11
AU2014277262B2 (en) 2019-10-03
CA2914500C (en) 2021-04-20
NO3003315T3 (enExample) 2018-06-16
JP2016520627A (ja) 2016-07-14
WO2014194975A1 (en) 2014-12-11
ES2663393T3 (es) 2018-04-12
EP3003315B1 (en) 2018-01-17
EP3003315A1 (en) 2016-04-13
US20160115154A1 (en) 2016-04-28
US9481668B2 (en) 2016-11-01
IL242915B (en) 2020-04-30
DK3003315T3 (en) 2018-04-16
CN105307656A (zh) 2016-02-03

Similar Documents

Publication Publication Date Title
JP6050335B2 (ja) チアゾール誘導体
JP6096797B2 (ja) ３−シアノアリール−１Ｈ−ピラゾロ［２．３−ｂ］ピリジン誘導体
JP6138831B2 (ja) ＴＢＫ１およびＩＫＫ阻害剤としてのフロ［３，２−ｂ］−およびチエノ［３，２−ｂ］ピリジン誘導体
JP2011529456A (ja) イミダゾチアジアゾール誘導体
JP5891234B2 (ja) １ｈ−ピロロ［２，３−ｂ］ピリジン誘導体
JP2009535300A (ja) キナーゼ阻害剤としての新規なシクロブチル化合物
EP1874760B1 (de) (lH-IND0L-7-YL)-(PYRIMIDIN-2 -YL-AMINO) METHANON DERIVATE UND VERWANDTE VERBINDUNGEN ALS IGF-Rl INHIBITOREN ZUR BEHANDLUNG VON KREBS
AU2014277262B2 (en) A quinoline inhibitor of the macrophage stimulating 1 receptor MST1 R
CN103717600B (zh) 吡啶并嘧啶衍生物
CN102666538B (zh) 吡咯并吡啶基嘧啶-2-基胺衍生物
CN104736543A (zh) 用于治疗肿瘤的7-氮杂吲哚-2,7-二氮杂萘衍生物
HK1194067A (en) Thiazole derivatives
HK1194067B (en) Thiazole derivatives

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170508

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180703

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181108

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20181210

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20181211

R150 Certificate of patent or registration of utility model

Ref document number: 6464395

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees